Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions
COVID-19
Interventions
DRUG

Molnupiravir (Esperavir)

Capsules 800 mg, 2 times a day with 12 ±2 hours interval for 5 days

DRUG

Standard of care

The administration of 'Standard of care' drugs was done according to the regimen recommended in the 'COVID-19 TreatmentGuidelines'(Version 14 of 27.12.2021), or inforce at the time of the study

Trial Locations (12)

Unknown

"Regional Budget Healthcare Institution Ivanovo clinical hospital", Ivanovo

Kirov State Medical University of Ministry of Health of the Russian Federation, Kirov

State Budgetary Healthcare Institution City Clinical Hospital named after S. I. Spasokukotskiy of Moscow Healthcare Department, Moscow

Professorskaya klinika, LLC, Perm

Ryazan State Medical University named after academician I.P. Pavlov of Ministry of Health of the Russian Federation, Ryazan

Avrora MedFort, LLC, Saint Petersburg

OrCli Hospital, LLC, Saint Petersburg

Ogarev Mordova State University of Ministry of Health of the Russian Federation, Saransk

"Regional State Budget Healthcare Institution Clinical hospital No. 1", Smolensk

Smolensk State Medical University of Ministry of Health of the Russian Federation, Smolensk

Uromed, LLC, Smolensk

"State Budgetary Healthcare Institution of Yaroslavl Region Clinical hospital No. 3", Yaroslavl

All Listed Sponsors
lead

Promomed, LLC

OTHER

NCT05595824 - Open Multicenter Study for Assessment of Efficacy and Safety of Molnupiravir in Adult Patients With COVID-19 | Biotech Hunter | Biotech Hunter